KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Invested Capital (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Invested Capital data on record, last reported at $5.4 billion in Q4 2025.

  • For Q4 2025, Invested Capital fell 47.48% year-over-year to $5.4 billion; the TTM value through Dec 2025 reached $5.4 billion, down 47.48%, while the annual FY2025 figure was $5.4 billion, 47.48% down from the prior year.
  • Invested Capital reached $5.4 billion in Q4 2025 per JAZZ's latest filing, down from $9.3 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $10.9 billion in Q2 2021 and bottomed at $5.4 billion in Q4 2025.
  • Average Invested Capital over 5 years is $9.1 billion, with a median of $9.4 billion recorded in 2024.
  • Peak YoY movement for Invested Capital: soared 107.24% in 2021, then plummeted 47.48% in 2025.
  • A 5-year view of Invested Capital shows it stood at $10.0 billion in 2021, then fell by 12.03% to $8.8 billion in 2022, then increased by 7.26% to $9.4 billion in 2023, then increased by 7.96% to $10.2 billion in 2024, then tumbled by 47.48% to $5.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were $5.4 billion in Q4 2025, $9.3 billion in Q3 2025, and $9.1 billion in Q2 2025.